Bausch + Lomb has named John Barr global president of the company’s surgical business. Mr. Barr will oversee the company’s full suite of ophthalmic surgical products, IOLs, and delivery systems, according to a company news release.
Immediately prior to joining Bausch + Lomb, Mr. Barr was president and CEO of AGA Medical, a maker of minimally invasive devices to treat structural heart defects and vascular abnormalities. During his 6 years with the company, Mr. Barr more than doubled sales, while gross margins expanded from 79% to 86%, according to Bausch + Lomb. Mr. Barr also spent more than 8 years at V.I. Technologies, an anti-infective therapeutics company, as its president and chief operating officer. Before joining V.I. Technologies, Mr. Barr spent 7 years with Haemonetics, a manufacturer of blood processing technology, in a variety of customer service and operations roles before being named president of North American operations.
Mr. Barr will be based at the company’s surgical headquarters in Aliso Viejo, California, and will report to Brent L. Saunders, chief executive officer of Bausch + Lomb. He will succeed Robert Grant, who left Bausch + Lomb in December 2011 and has since founded a private equity fund, Strathspey Crown LLC.
TOP 5 ARTICLES FROM 2012
- Piggyback IOLs for Residual Refractive Error After Cataract Surgery
An overview of the indications, contraindications, surgical technique, and complications.
By Jonathan B. Rubenstein, MD
- When My Time for Cataract Surgery Comes
Five surgeons were asked to choose an IOL for their own cataract procedure and explain the rationale for their choices.
By Neiel Baronberg, MD; Steven J. Dell, MD; Mark Packer, MD, CPI; Audrey R. Talley-Rostov, MD; and Robert J. Cionni, MD
- Presbyopia Update 2012: New Technologies and Novel Treatments
By Mitchell C. Shultz, MD
- IOL Choice and Calculations in a Post-RK Patient
By David R. Hardten, MD; Warren E. Hill, MD; William B. Trattler, MD; R. Bruce Wallace III, MD; And Robert T. Crotty, OD
- Cataract Surgery Complication Rates: How Are We Doing?
The femtosecond laser has the potential to improve cataract surgical outcomes and reduce complications, but studies must test this hypothesis.
By David F. Chang, MD